POINT’s Late-Stage Study on Cancer Treatment Reveals Promising Findings

Lantheus and POINT Biopharma shared promising outcomes of a late-stage study on their prostate cancer treatment. Meanwhile, Eli Lilly has pushed back the closing date for its buyout offer. 

The research showed that the treatment had a noticeably longer median time without tumor growth at 9 months, while alternative therapies such as androgen receptor pathway inhibitors had a shorter time of 6 months. This suggests a 29% lower risk of tumor growth. 

In the late-stage study, which involved more than 400 patients from multiple countries, just over 80% of individuals in the control group switched to POINT’s therapy when their illness developed.  

Neil Fleshner, the leading medical executive, commented, “The success of 177Lu-PNT2002 in this trial demonstrates the value of treating patients with radioligand therapy at this stage of the disease continuum.” 

Fleshner went on to add, “With only four treatment administrations over 32 weeks, this regimen provides reduced treatment intensity compared to the control arm, while also delaying disease progression with lower toxicity.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.